New migraine drugs under way

Researchers are working on new treatments for migraine attacks that cause fewer adverse reactions, including strokes, heart attacks and cognitive problems, a British migraine expert said. Tonabersat, which belongs to a new class of medicines called gap-junction blockers, is undergoing early clinical trials as a preventive medication for the condition. Other compounds that block the calcitonin gene-related peptide -- found at elevated levels in the brains of migraine patients -- are being developed to relieve symptoms without constricting blood vessels.

View Full Article in:

BBC · Independent (London) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX